Servier and CTI BioPharma have agreed to expand their existing licence and development collaboration agreement for Pixuvri (pixantrone).
Under this expanded agreement, Servier will have commercialisation rights of Pixuvri in all markets except the US, where CTI BioPharma will retain its rights.
Go deeper with GlobalData
Servier will pay €12m to CTI BioPharma for this expanded commercial rights.
CTI BioPharma can receive nearly €76m considering additional sales, regulatory milestone payments with royalties on net product sales.
Pixuvri is a cytotoxic medicine indicated as monotherapy to treat adult patients suffering from relapsed or refractory aggressive non-Hodgkin B-cell Lymphoma (NHL).
See Also:
Servier therapeutic area oncology head Dr Marion Schrenk said: “Over the past three years, we have worked hand-in-hand with our partner, CTI BioPharma, to bring new treatment options to patients in Europe.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We are looking forward to leveraging our expertise in these additional markets to ensure more eligible patients have access to Pixuvri.
“Oncology is an important focus for us, and we are fully committed to working with our partners, researchers and scientists to provide patients with novel therapeutic options in areas with high unmet needs.”
Pixuvri has already received conditional approval from the European Medicines Agency.
Under the specific post-authorisation requirement, Pixuvri is currently being investigated in Phase III clinical trial PIX306.
If the trial is successful, the results will confirm the current indication and it can also support further indications.
CTI BioPharma president and CEO Adam Craig said: “Servier is an important strategic partner for us and has helped bring PIXUVRI to many patients.
“We look forward to our expanded partnership as we aim to complete the PIX306 trial in the near-term.”
Servier received the rights in 2014 to commercialise Pixuvri globally except in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the UK and the US.
The expanded agreement with Servier will extend its licencing area to all the aforementioned countries except the US.
